GLP-1受体激动剂与2型糖尿病癫痫风险关联
本研究基于TriNetX网络2015至2023年数据,纳入倾向评分匹配后的452,766例成人2型糖尿病患者,比较GLP-1受体激动剂与DPP-4抑制剂新使用者的癫痫发生风险。结果显示GLP-1受体激动剂组癫痫风险显著低于DPP-4抑制剂组(HR 0.84,95%CI 0.78-0.90),司美格鲁肽关联最强(HR 0.68,95%CI 0.60-0.77)。
要点
- GLP-1受体激动剂组癫痫风险显著低于DPP-4抑制剂组(HR 0.84)。
- 司美格鲁肽与癫痫风险降低关联最强(HR 0.68)。
- 保护性关联在1年、3年、5年随访中均可见。
核心结论
- 在成人2型糖尿病患者中,GLP-1受体激动剂治疗与较DPP-4抑制剂使用更低的癫痫风险相关。
研究设计与样本
- 回顾性队列研究,使用TriNetX网络2015至2023年数据,纳入18岁及以上2型糖尿病新使用GLP-1受体激动剂或DPP-4抑制剂者,排除既往癫痫或惊厥诊断或使用抗癫痫药物者,经1:1倾向评分匹配后共452,766例(每组226,383例,平均年龄60.5岁,女性47.1%)。
主要发现
- 随访期间GLP-1受体激动剂组1,670例、DPP-4抑制剂组1,886例发生癫痫,累积发病率分别为2.35%与2.41%。
- GLP-1受体激动剂使用与显著更低的癫痫风险相关(HR 0.84,95%CI 0.78-0.90)。
- 保护性关联在1年(HR 0.71,95%CI 0.62-0.80)、3年(HR 0.81,95%CI 0.74-0.88)和5年(HR 0.82,95%CI 0.76-0.88)均可见。
- 单个药物中司美格鲁肽关联最强(HR 0.68,95%CI 0.60-0.77)。
- 排除重叠或转换暴露的敏感性分析结果相似(HR 0.71,95%CI 0.64-0.78)。
关键数值与推荐
- 主要结局为 incident epilepsy,使用ICD-10-CM编码识别。
- 采用Cox比例风险模型估计HR及95%CI。
- 证据等级为Class III,提示GLP-1受体激动剂与较低癫痫风险相关。
临床怎么用
- 对于合并2型糖尿病的成人,选择GLP-1受体激动剂(尤其司美格鲁肽)可能附带降低癫痫风险的获益。
- 该观察性证据支持GLP-1受体激动剂可能具有超越血糖控制的神经保护作用,但需结合患者个体情况综合决策。
局限性
- 观察性设计可能存在残余混杂。
- 研究基于数据库编码识别结局,可能存在错分偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) are at an increased risk of developing epilepsy, particularly in later life. While preclinical studies suggest neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), real-world comparative effectiveness data remain limited. We aimed to evaluate whether GLP-1 RA use is associated with a lower risk of incident epilepsy compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use in adults with T2DM. METHODS: We conducted a retrospective cohort study using the TriNetX network from 2015 to 2023, including adults aged 18 years or older with T2DM who were new users of either GLP-1 RAs or DPP-4is. Patients with a previous diagnosis of epilepsy or seizure, or those using antiepileptic drugs, were excluded. The primary outcome was incident epilepsy, identified using ICD-10-CM codes. Propensity score matching (1:1) was performed based on demographics, socioeconomic status, body mass index, comorbidities, and baseline medications. Cox proportional hazard models estimated hazard ratios (HRs) with 95% CIs. We also conducted prespecified subgroup and sensitivity analyses to assess the robustness of the findings. RESULTS: After matching, 452,766 patients were included (226,383 in each group; mean age 60.5 years; 47.1% female). During follow-up, 1,670 individuals in the GLP-1 RA group and 1,886 in the DPP-4i group developed epilepsy, corresponding to cumulative incidences of 2.35% vs 2.41%. GLP-1 RA use was associated with a significantly lower risk of epilepsy (HR 0.84, 95% CI 0.78-0.90), with protective associations evident at 1 year (HR 0.71, 95% CI 0.62-0.80), 3 years (HR 0.81, 95% CI 0.74-0.88), and 5 years (HR 0.82, 95% CI 0.76-0.88). Among individual agents, semaglutide showed the strongest association (HR 0.68, 95% CI 0.60-0.77). The results were consistent across major subgroups, including both age and sex. Sensitivity analyses excluding patients with overlapping or switching exposure yielded similar findings (HR 0.71, 95% CI 0.64-0.78). DISCUSSION: GLP-1 RA therapy was associated with a significantly lower epilepsy risk compared with DPP-4i use in adults with T2DM. These results support the hypothesis that GLP-1 RAs may exert neurologic benefits beyond glycemic control. Limitations include the observational design and potential residual confounding. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the use of GLP-1 RAs in people with T2DM results in a lower risk of developing epilepsy compared with those treated with DPP-4i.
引用
- Cheng CY, Lo SC, Huang CN, et al. Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes. Neurology. 2025. PMID: 41370744. doi:10.1212/WNL.0000000000214509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。